Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung

Richard J. Gralla, B. G. Raphael, R. B. Golbey, C. W. Young

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Fifty-two patients with non-small cell carcinoma of the lung were treated iv with doses of vindesine at 3-4 mg/m2/week iv. Partial responses occurred in all histologic types in ten of 46 adequately treated patients, for an overall response rate of 22%. Patients not previously treated with chemotherapy had a higher response rate than those who had received prior chemotherapy (33% versus 12%). Reversible peripheral neuropathy occurred in all patients, and was generally of a mild to moderate degree. Mild leukopenia was seen frequently, with a median wbc nadir of 2900/mm3. As reported with the older vinca alkaloids, platelet-sparing with occasional episodes of thromboyctosis occurred with vindesine. It is concluded that vindesine is an active agent in non-small cell carcinoma of the lung and that further studies in previously untreated patients are indicated.

Original languageEnglish (US)
Pages (from-to)1343-1346
Number of pages4
JournalCancer Treatment Reports
Volume63
Issue number8
StatePublished - 1979
Externally publishedYes

Fingerprint

Vindesine
Non-Small Cell Lung Carcinoma
Vinca Alkaloids
Drug Therapy
Leukopenia
Peripheral Nervous System Diseases
Blood Platelets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gralla, R. J., Raphael, B. G., Golbey, R. B., & Young, C. W. (1979). Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treatment Reports, 63(8), 1343-1346.

Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. / Gralla, Richard J.; Raphael, B. G.; Golbey, R. B.; Young, C. W.

In: Cancer Treatment Reports, Vol. 63, No. 8, 1979, p. 1343-1346.

Research output: Contribution to journalArticle

Gralla, RJ, Raphael, BG, Golbey, RB & Young, CW 1979, 'Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung', Cancer Treatment Reports, vol. 63, no. 8, pp. 1343-1346.
Gralla, Richard J. ; Raphael, B. G. ; Golbey, R. B. ; Young, C. W. / Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. In: Cancer Treatment Reports. 1979 ; Vol. 63, No. 8. pp. 1343-1346.
@article{8e0b021df97346cbac55f11906572a7f,
title = "Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung",
abstract = "Fifty-two patients with non-small cell carcinoma of the lung were treated iv with doses of vindesine at 3-4 mg/m2/week iv. Partial responses occurred in all histologic types in ten of 46 adequately treated patients, for an overall response rate of 22{\%}. Patients not previously treated with chemotherapy had a higher response rate than those who had received prior chemotherapy (33{\%} versus 12{\%}). Reversible peripheral neuropathy occurred in all patients, and was generally of a mild to moderate degree. Mild leukopenia was seen frequently, with a median wbc nadir of 2900/mm3. As reported with the older vinca alkaloids, platelet-sparing with occasional episodes of thromboyctosis occurred with vindesine. It is concluded that vindesine is an active agent in non-small cell carcinoma of the lung and that further studies in previously untreated patients are indicated.",
author = "Gralla, {Richard J.} and Raphael, {B. G.} and Golbey, {R. B.} and Young, {C. W.}",
year = "1979",
language = "English (US)",
volume = "63",
pages = "1343--1346",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung

AU - Gralla, Richard J.

AU - Raphael, B. G.

AU - Golbey, R. B.

AU - Young, C. W.

PY - 1979

Y1 - 1979

N2 - Fifty-two patients with non-small cell carcinoma of the lung were treated iv with doses of vindesine at 3-4 mg/m2/week iv. Partial responses occurred in all histologic types in ten of 46 adequately treated patients, for an overall response rate of 22%. Patients not previously treated with chemotherapy had a higher response rate than those who had received prior chemotherapy (33% versus 12%). Reversible peripheral neuropathy occurred in all patients, and was generally of a mild to moderate degree. Mild leukopenia was seen frequently, with a median wbc nadir of 2900/mm3. As reported with the older vinca alkaloids, platelet-sparing with occasional episodes of thromboyctosis occurred with vindesine. It is concluded that vindesine is an active agent in non-small cell carcinoma of the lung and that further studies in previously untreated patients are indicated.

AB - Fifty-two patients with non-small cell carcinoma of the lung were treated iv with doses of vindesine at 3-4 mg/m2/week iv. Partial responses occurred in all histologic types in ten of 46 adequately treated patients, for an overall response rate of 22%. Patients not previously treated with chemotherapy had a higher response rate than those who had received prior chemotherapy (33% versus 12%). Reversible peripheral neuropathy occurred in all patients, and was generally of a mild to moderate degree. Mild leukopenia was seen frequently, with a median wbc nadir of 2900/mm3. As reported with the older vinca alkaloids, platelet-sparing with occasional episodes of thromboyctosis occurred with vindesine. It is concluded that vindesine is an active agent in non-small cell carcinoma of the lung and that further studies in previously untreated patients are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0018635613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018635613&partnerID=8YFLogxK

M3 - Article

C2 - 225028

AN - SCOPUS:0018635613

VL - 63

SP - 1343

EP - 1346

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8

ER -